LTZ Therapeutics

LTZ Therapeutics is a private, preclinical-stage biotech founded in 2020, headquartered in Redwood City, California, with operations in San Diego and Shenzhen, China. The company is pioneering a novel class of immunotherapies called myeloid cell engagers (MCEs), designed to activate the innate immune system's myeloid cells to attack tumors and overcome immunosuppressive microenvironments. A significant strategic collaboration with GSK, announced in late 2025, validates its platform and provides non-dilutive funding and development support. LTZ operates as a platform company, leveraging its proprietary technology to build a pipeline of MCE candidates aimed at addressing significant unmet needs in oncology.

Proprietary Myeloid Cell Engager (MCE) platform designed to create bi/multi-specific molecules that directly activate myeloid cells (e.g., macrophages) to kill tumor cells via phagocytosis, reprogram the immunosuppressive tumor microenvironment, and stimulate adaptive T-cell immunity for durable responses.

LTZ operates in the emerging and competitive field of myeloid-targeting immunotherapies, competing with companies developing CD47/SIRPα inhibitors, CCR2/5 antagonists, and other macrophage-focused modalities. Its differentiation lies in its specific engager approach designed to directly trigger phagocytosis and reprogram the TME. The GSK partnership aligns it with a major pharmaceutical player in oncology.